Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) and PreveCeutical Medical (OTCMKTS:PRVCF – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership and profitability.
Profitability
This table compares Enliven Therapeutics and PreveCeutical Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Enliven Therapeutics | N/A | -24.88% | -23.96% |
| PreveCeutical Medical | N/A | N/A | -1,106.11% |
Earnings & Valuation
This table compares Enliven Therapeutics and PreveCeutical Medical”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Enliven Therapeutics | N/A | N/A | -$89.02 million | ($1.84) | -11.36 |
| PreveCeutical Medical | N/A | N/A | -$860,000.00 | N/A | N/A |
Analyst Recommendations
This is a summary of recent ratings and target prices for Enliven Therapeutics and PreveCeutical Medical, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Enliven Therapeutics | 1 | 0 | 5 | 0 | 2.67 |
| PreveCeutical Medical | 0 | 0 | 0 | 0 | 0.00 |
Enliven Therapeutics currently has a consensus target price of $41.20, indicating a potential upside of 97.06%. Given Enliven Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Enliven Therapeutics is more favorable than PreveCeutical Medical.
Institutional and Insider Ownership
95.1% of Enliven Therapeutics shares are owned by institutional investors. 25.9% of Enliven Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Risk and Volatility
Enliven Therapeutics has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500. Comparatively, PreveCeutical Medical has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500.
Summary
Enliven Therapeutics beats PreveCeutical Medical on 6 of the 9 factors compared between the two stocks.
About Enliven Therapeutics
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.
About PreveCeutical Medical
PreveCeutical Medical Inc., a health sciences company, engages in the development of options for preventive and curative therapies utilizing organic and nature identical products. Its pipeline products include Cannabinoid Sol-Gel Delivery, a cannabinoid-based nose-to-brain delivery system that provides relief from various indications, including pain, inflammation, seizures, and neurological disorders; Non-Addictive Analgesic for pain management; BSV Peptide Program that targets cancer progression; and Dual Gene Therapy for type 2 diabetes and obesity. PreveCeutical Medical Inc. is headquartered in West Vancouver, Canada.
Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
